Cargando…

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma

BACKGROUND: Unresectable or metastatic vulvar cancer has relatively poor outcomes despite chemotherapy-sensitized radiation therapy and combination cytotoxic therapy. Despite the virus-associated and immunogenic nature of this disease, novel immunotherapy options that exploit this advantage are curr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeku, Oladapo, Russo, Andrea L., Lee, Hang, Spriggs, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491059/ https://www.ncbi.nlm.nih.gov/pubmed/32928237 http://dx.doi.org/10.1186/s12967-020-02523-5

Ejemplares similares

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma
por: Lin, Charles, et al.
Publicado: (2021)

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
por: How, Jeffrey A., et al.
Publicado: (2021)

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
por: Bando, Hideaki, et al.
Publicado: (2020)

Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma
por: Bergstrom, Jennifer, et al.
Publicado: (2015)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

A comparative study of cisplatin-based definitive chemo-radiation in non-metastatic squamous cell carcinoma of the esophagus
por: Mofid, Bahram, et al.
Publicado: (2016)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017)

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial
por: Rutten, V. C., et al.
Publicado: (2023)

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
por: Garrido, Pilar, et al.
Publicado: (2017)

The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer
por: Reale, Maria Lucia, et al.
Publicado: (2020)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Spindle Cell Squamous Cell Carcinoma of the Scalp Treated With Pembrolizumab Cisplatin and 5-Fluorouracil
por: Alzahrani, Ali M, et al.
Publicado: (2021)

Quality of Life with Vulvar Carcinoma Treated with Palliative Electrochemotherapy: The ELECHTRA (ELEctroCHemoTherapy vulvaR cAncer) Study
por: Perrone, Anna Myriam, et al.
Publicado: (2021)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
por: Shang, Xiaobin, et al.
Publicado: (2022)

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
por: Tanzawa, Shigeru, et al.
Publicado: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
por: Kim, Stefano, et al.
Publicado: (2020)

Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results
por: Ojima, Toshiyasu, et al.
Publicado: (2019)

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol
por: Modesto, Anouchka, et al.
Publicado: (2023)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation
por: Munoz, Fernando, et al.
Publicado: (2007)

Electrochemotherapy in Vulvar Cancer and Cisplatin Combined with Electroporation. Systematic Review and In Vitro Studies
por: Perrone, Anna Myriam, et al.
Publicado: (2021)

Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy
por: McCall, Neal S., et al.
Publicado: (2022)

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
por: Hughes, Ryan T, et al.
Publicado: (2023)

Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China
por: Li, Jieying, et al.
Publicado: (2022)

Vulvar intraepithelial neoplasia: Incidence and long‐term risk of vulvar squamous cell carcinoma
por: Thuijs, Nikki B., et al.
Publicado: (2020)

The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma
por: Garganese, Giorgia, et al.
Publicado: (2021)

Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab: A case report
por: Nozawa, Yoshihiro, et al.
Publicado: (2018)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma: a proposed protocol for a multicentre observational study
por: van Doorn, Helena C., et al.
Publicado: (2022)

Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer
por: Yamaguchi, Kensei, et al.
Publicado: (2022)

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
por: Yeku, Oladapo O., et al.
Publicado: (2021)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Molecular Landscape of Vulvar Squamous Cell Carcinoma
por: Carreras-Dieguez, Núria, et al.
Publicado: (2021)

Transcriptome Analysis in Vulvar Squamous Cell Cancer
por: Prieske, Katharina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sptm2sl42p1ftec3tdintkts2n